v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating activities:      
Net income $ 15,909 $ 41,980 $ 145,523
Adjustments to reconcile net income to net cash provided by operating activities:      
Deferred taxes (7,945) 10,872 (126,613)
Depreciation of fixed assets and amortization of intangible assets 91,501 28,548 19,908
Amortization of debt issuance costs 4,400 2,754 2,156
Amortization of debt discount 2,807 23,152 18,254
Loss (gain) on disposal of fixed assets 193 (10) 22
Loss on early extinguishment of debt 0 0 8,071
Stock-based compensation 48,092 42,246 39,920
Changes in contingent consideration (29,476) (989) 5,204
Impairment of indefinite-lived intangible asset 26,134 0 0
Impairment of investment 10,000 0 0
Loss (gain) on investment and other non-operating income, net 92 2,673 (1,618)
Changes in operating assets and liabilities:      
Accounts receivable, net (2,079) (10,434) (5,516)
Inventories, net 2,486 (4,467) (6,353)
Prepaid expenses and other assets (2,699) 1,142 (739)
Accounts payable 6,272 (10,262) (3,312)
Accrued expenses and income taxes payable (19,857) 5,451 (5,999)
Other liabilities (556) (104) (2,467)
Payment of contingent consideration 0 (6,835) (9,409)
Net cash provided by operating activities 145,274 125,717 77,032
Investing activities:      
Acquisition of Flexion Therapeutics, Inc. (net of cash acquired) 0 (420,042) 0
Purchases of fixed assets (30,076) (45,866) (37,801)
Purchases of available-for-sale investments (387,685) (611,488) (546,516)
Sales of available-for-sale investments 237,576 1,068,736 307,870
Payment of contingent consideration (32,000) (4,000) 0
Sale of equity investment 0 9,057 0
Purchases of equity and debt investments (13,000) (17,187) (1,160)
Net cash used in investing activities (225,185) (20,790) (277,607)
Financing activities:      
Proceeds from exercises of stock options 24,387 23,844 45,218
Proceeds from common stock issued under employee stock purchase plan 2,954 2,811 2,546
Proceeds from Term loan B facility maturing December 2026 0 363,750 0
Repayment of Term loan B facility maturing December 2026 (78,125) 0 0
Payment of debt issuance and financing costs (1,175) (4,546) (12,487)
Payment of contingent consideration 0 (5,165) (5,591)
Net cash (used) provided by financing activities (401,528) 380,694 222,304
Net (decrease) increase in cash and cash equivalents (481,439) 485,621 21,729
Cash and cash equivalents, beginning of year 585,578 99,957 78,228
Cash and cash equivalents, end of year 104,139 585,578 99,957
Supplemental cash flow information:      
Cash paid for interest 33,295 6,996 7,205
Cash paid for income taxes, net of refunds 7,398 3,221 2,417
Non-cash investing and financing activities:      
Issuance of common stock from conversion of 2022 convertible senior notes 3,040 0 0
Fixed assets included in accounts payable and accrued liabilities 5,888 6,828 9,288
Net additions to contingent consideration liabilities 0 45,241 0
Convertible Senior Notes Due 2025      
Financing activities:      
Proceeds from debt component of the 2025 convertible senior notes 0 0 314,708
Proceeds from equity component of the 2025 convertible senior notes 0 0 87,792
Convertible Senior Notes Due 2022      
Financing activities:      
Repayments of convertible senior notes (156,960) 0 (176,793)
Retirement of equity component of the 2022 convertible senior notes 0 0 (33,089)
Convertible Senior Notes Due 2024      
Financing activities:      
Repayments of convertible senior notes $ (192,609) $ 0 $ 0